2017-11-15T13:56:10-06:00 2016-12-31 271235638 MOUNTJOY CHILTON MEDLEY LLP 462 S FOURTH ST SUITE 2600 LOUISVILLE KY 402023445 990 2016-01-01 830392250 NATIONAL STEM CELL FOUNDATION INC NATI 5023798544 462 S 4TH STREET NO 1230 LOUISVILLE KY 40202 DR PAULA GRISANTI CHAIRMAN 5023798544 2017-11-15 1 REBECCA L PHILLIPS CPA P00024055 5027491900 128.136.148.166 2017-11-15 14:29:38 ES P 67686B56B41F7CCF39B57D3FBA82A7CCB21CF855 7CC221E31CECBAC677BF5A98758DEE4845ABB877 2016 2021-01-29 14:40:06Z DR PAULA GRISANTI 462 S 4TH STREET NO 1230 LOUISVILLE KY 40202 1170610 0 X WWW.NATIONALSTEMCELLFOUNDATION.ORG X 2003 DC NSCF FUNDS ADULT STEM CELL RESEARCH, SCHOLARSHIPS FOR MIDDLE-SCHOOL (CONTINUED ON SCHEDULE O)SCIENCE TEACHERS, EFFORTS TO INCREASE THE DONOR POOL FOR BONE MARROW TRANSPLANTS AND PROGRAMS THAT CONNECT CHILDREN WITH LIMITED RESOURCES TO CLINICAL TRIALS FOR RARE DISEASES. 5 3 4 4 0 0 965688 695941 0 0 123955 44135 0 0 1089643 740076 1739366 952070 0 0 456779 360727 0 0 102169 342014 231449 2538159 1544246 -1448516 -804170 4643001 4203563 1331551 1583833 3311450 2619730 X NSCF FUNDS ADULT STEM CELL RESEARCH, SCHOLARSHIPS FOR MIDDLE-SCHOOL SCIENCE TEACHERS, EFFORTS TO INCREASE THE DONOR POOL FOR BONE MARROW TRANSPLANTS AND PROGRAMS THAT CONNECT CHILDREN WITH LIMITED RESOURCES TO CLINICAL TRIALS FOR RARE DISEASES. 1 0 1326480 952070 ACCOMPLISHMENTS INCLUDE DEVELOPMENT OF A COLLABORATIVE PROJECT BETWEEN FUNDED RESEARCHERS ON BOTH COASTS GOING TO THE INTERNATIONAL SPACE STATION (ISS) TO ADVANCE SCIENCE IN THE FIELD OF NEURODEGENERATIVE DISEASE. CONNECTING RESEARCH TO EDUCATION, ASTRONAUTS ON THE ISS WILL SPEAK TO STUDENTS IN MIDDLE SCHOOL CLASSROOMS AFFILIATED WITH THE NATIONAL STEM (SCIENCE, TECHNOLOGY, ENGINEERING & MATH) SCHOLAR PROGRAM. ALSO THE DEVELOPMENT OF A SECOND PARTNERSHIP WITH THE ORTHOPAEDIC RESEARCH & EDUCATION FOUNDATION (OREF) TO FUND CLINICAL TRIALS TO REPAIR/REGENERATE BONE, MUSCLE OR TENDONS, AND A NEW FUND AT DUKE UNIVERSITY'S PEDIATRIC BLOOD & MARROW TRANSPLANT (PBMT) PROGRAM TO HELP CHILDREN OF LIMITED MEANS PARTICIPATE IN CLINICAL TRIALS TO ADVANCE RESEARCH INTO THERAPIES FOR RARE DISEASES. 1326480 1 1 0 0 0 0 0 0 0 0 1 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 8 0 1 4 1 0 0 0 0 0 0 0 0 0 0 X 5 3 1 1 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 KY X DR PAULA GRISANTI 5023798544 462 S 4TH STREET SUITE 1230 LOUISVILLE KY 40202 PAULA GRISANTI CHAIRMAN AND CEO 40.00 X X 200000 0 2165 C DENNIS RIGGS SECRETARY/TREASURER 1.00 X X 0 0 0 MICHAEL GRISANTI DIRECTOR 2.00 X 0 0 0 BRUCE S WOLFF DIRECTOR 5.00 X 0 0 0 JOHN M CRANOR III DIRECTOR 1.00 X 0 0 0 DIANE CORNWELL CHIEF FINANCIAL OFFICER 1.30 X 15100 0 0 215100 0 2165 1 0 1 0 0 695941 695941 55306 55306 419363 430534 -11171 -11171 -11171 740076 0 0 44135 952070 952070 217634 167026 30161 20447 114384 53366 15750 45268 8395 3917 1156 3322 20314 9478 2797 8039 3090 3090 40894 1340 39554 13798 13798 2044 953 281 810 49392 44477 4915 21770 10596 4218 6956 35369 23469 4037 7863 4907 4380 527 5425 5425 18615 12352 2125 4138 28225 26621 1193 411 TRANSFER PROGRAM ASSETS 7920 7920 1544246 1326480 115597 102169 1216879 687371 117338 95815 13338 12654 97358 54191 61782 43167 2954029 3086171 279635 278385 4643001 4203563 27447 49659 1304104 1534174 1331551 1583833 X 3244112 2523841 67338 95889 3311450 2619730 4643001 4203563 X -804170 100420 12030 0 X X 0 1 X 1 0 X 313050 112193 1004349 965688 697650 3092930 313050 112193 1004349 965688 697650 3092930 1973703 1119227 441 550 12061 45957 55306 114315 7830 1572 9402 3216647 250000 0.34790 0.38900 X SCHEDULE A, PART VI, LIST OF UNUSUAL GRANTS: DESCRIPTION: CASH DATE: 12/01/12 AMOUNT: 250000. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5476 2738 2738 91882 51453 40429 43167 INVESTMENT 3086171 F 3086171 OTHER PROGRAM RELATED ASSETS 278385 278385 X 862538 100420 10871 111291 751247 -11171 -11171 740076 1516288 10871 -38829 -27958 1544246 0 1544246 PART X, LINE 2: THE FOUNDATION HAS RECEIVED A DETERMINATION LETTER FROM THE INTERNAL REVENUE SERVICE INDICATING THAT IT IS EXEMPT FROM INCOME TAXES UNDER SECTION 501(C)(3) OF INTERNAL REVENUE CODE AND IS CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION. ACCORDINGLY, NO PROVISION FOR INCOME TAXES IS INCLUDED IN THE FINANCIAL STATEMENTS. THE FOUNDATION RECOGNIZES UNCERTAIN INCOME TAX POSITIONS USING THE "MORE-LIKELY-THAN-NOT" APPROACH AS DEFINED IN THE ASC. NO LIABILITY FOR UNCERTAIN TAX POSITIONS HAS BEEN RECORDED IN THE ACCOMPANYING FINANCIAL STATEMENTS. PART XI, LINE 4B - OTHER ADJUSTMENTS: LOSS ON SALE OF SECURITIES -11,171. PART XII, LINE 2D - OTHER ADJUSTMENTS: LOSS ON SALE OF SECURITIES 11,171. RETURNED GRANT -50,000. 1 KENTUCKY SCIENCE AND TECHNOLOGY CORPORATION 200 W VINE ST LEXINGTON KY 40507 611135362 501(C)(3) 250000 SEE PART IV SUPPLEMENTAL INFORMATION NORTHWESTERN MEMORIAL HEALTHCARE 251 E HURON ST CHICAGO IL 60611 363152959 501(C)(3) 100000 SEE PART IV SUPPLEMENTAL INFORMATION DUKE UNIVERSITY HEALTH SYSTEM FOR PBMT PROGRAM 2301 ERWIN RD DURHAM NC 27710 562070036 501(C)(3) 200000 SEE PART IV SUPPLEMENTAL INFORMATION OREF 9400 W HIGGINS RD ROSEMONT IL 60018 366009467 501(C)(3) 300000 SEE PART IV SUPPLEMENTAL INFORMATION 4 0 PART I, LINE 2: THE ORGANIZATION MEETS REGULARLY WITH REPRESENTATIVES FROM THE GRANT RECIPIENT(S) AND RECEIVES UPDATES AND REPORTS REGARDING EXPENDITURE OF THE FUNDS. PART II, LINE 1, COLUMN (H): NAME OF ORGANIZATION OR GOVERNMENT: KENTUCKY SCIENCE AND TECHNOLOGY CORPORATION (H)FUND A RESEARCH PROJECT TO THE INTERNATIONAL SPACE STATION (ISS) IN COLLABORATION WITH RESEARCHERS AT THE SCRIPPS RESEARCH INSTITUTE AND THE NEW YORK STEM CELL RESEARCH FOUNDATION. NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN MEMORIAL HEALTHCARE (H)SUPPORT IMMUNE MONITORING OF RENAL TRANSPLANT PATIENTS TREATED IN A CLINICAL TRIAL AT NORTHWESTERN MEMORIAL HOSPITAL. NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY HEALTH SYSTEM (H)UNDERWRITE INSURANCE DEDUCTIBLES AND CO-PAYS FOR THE FAMILIES OF CHILDREN ELIGIBLE BUT FINANCIALLY UNABLE TO PARTICIPATE IN CLINICAL TRIALS FOR RARE DISEASES AT DUKE UNIVERSITY'S PEDIATRIC BLOOD AND MARROW TRANSPLANT PROGRAM. NAME OF ORGANIZATION OR GOVERNMENT: OREF (H)FUND A MULTI-YEAR PEER-REVIEWED GRANT SUPPORTING ADULT STEM CELL RESEARCH IN A CLINICAL TRIAL TO ADVANCE THERAPIES IN ORTHOPEDIC MEDICINE. X X X X 0 0 0 0 0 0 0 0 0 PAULA GRISANTI CHAIRMAN AND CEO 200000 0 0 0 0 0 0 0 2165 0 202165 0 0 0 X 3 552106 FMV 0 0 0 0 FORM 990, PART III, LINE 2 THE FOUNDATION BEGAN TWO NEW PROGRAM SERVICES DURING THE YEAR: A PATIENT ADVOCACY PROGRAM THAT HELPS FAMILIES OF LIMITED MEANS PARTICIPATE IN CLINICAL TRIALS FOR THE TREATMENT OF CURRENTLY INCURABLE RARE DISEASES. COLLABORATIONS BETWEEN FUNDED RESEARCHERS FOR STUDIES IN ZERO GRAVITY TO ADVANCE SCIENCE IN THE NATIONAL STEM CELL FOUNDATION'S FUNDED AREAS. FORM 990, PART VI, SECTION A, LINE 2 PAULA GRISANTI, CHAIRMAN OF THE BOARD, AND MICHAEL GRISANTI, DIRECTOR, HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 3 THE ORGANIZATION HAS CONTRACTED ITS FINANCIAL MANAGEMENT OVERSIGHT TO AN OUTSIDE CHIEF FINANCIAL OFFICER AND ITS DAY TO DAY FINANCIAL DUTIES TO A CONTROLLER. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM AND REVIEWED IN DETAIL BY THE CONTRACT CFO, CONTRACT CONTROLLER, BOARD CHAIR AND FINANCE COMMITTEE. A COPY WAS THEN SENT TO EACH BOARD MEMBER FOR THEIR REVIEW BEFORE THE FORM 990 WAS FILED. FORM 990, PART VI, SECTION B, LINE 12C INTERESTED PERSONS WILL ANNUALLY DISCLOSE OR UPDATE TO THE CHAIRMAN OF THE BOARD OF DIRECTORS ON A FORM PROVIDED BY THE ORGANIZATION THEIR INTERESTS THAT COULD GIVE RISE TO CONFLICTS OF INTEREST, SUCH AS A LIST OF FAMILY MEMBERS, SUBSTANTIAL BUSINESS OR INVESTMENT HOLDINGS AND OTHER TRANSACTIONS OR AFFILIATION WITH BUSINESSES AND OTHER ORGANIZATIONS OR THOSE OF FAMILY MEMBERS. FOR EACH INTEREST DISCLOSED TO THE CHAIRMAN OF THE BOARD OF DIRECTORS, THE CHAIRMAN WILL DETERMINE WHETHER TO: (A) TAKE NO ACTION; (B) ASSURE FULL DISCLOSURE TO THE BOARD OF DIRECTORS AND OTHER INDIVIDUALS COVERED BY THE POLICY; (C) ASK THE PERSON TO RECUSE FROM PARTICIPATION IN RELATED DISCUSSIONS OR DECISION WITHIN THE ORGANIZATION; OR (D) ASK THE PERSON TO RESIGN FROM HIS OR HER POSITION IN THE ORGANIZATION OR, IF THE PERSON REFUSES TO RESIGN, BECOME SUBJECT TO POSSIBLE REMOVAL IN ACCORDANCE WITH THE ORGANIZATION'S REMOVAL PROCEDURES. THE ORGANIZATION'S CHIEF EMPLOYED EXECUTIVE AND CHIEF EMPLOYED FINANCE EXECUTIVE WILL MONITOR PROPOSED OR ONGOING TRANSACTIONS FOR CONFLICTS OF INTEREST AND DISCLOSE THEM TO THE CHAIRMAN OF THE BOARD OF DIRECTORS IN ORDER TO DEAL WITH POTENTIAL OR ACTUAL CONFLICTS, WHETHER DISCOVERED BEFORE OR AFTER THE TRANSACTION HAS OCCURRED. TO DATE NO POTENTIAL CONFLICTS HAVE BEEN IDENTIFIED. FORM 990, PART VI, SECTION B, LINE 15 IN 2015 THE BOARD ENGAGED AN OUTSIDE CONSULTING FIRM TO DETERMINED AN APPROPRIATE SALARY RANGE FOR THE CHAIR/CEO POSITION. A BOARD APPROVED SALARY WAS ESTABLISHED BASED ON THEIR GUIDANCE AND NO SALARY ADJUSTMENT HAS BEEN MADE SINCE THAT TIME. CONTRACTED CFO AND CONTRACTED CONTROLLER ARE PAID ON AN HOURLY BASIS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XII, LINE 2C: THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. THE ORGANIZATION'S BOARD OF DIRECTORS CONTINUE TO SELECT THE INDEPENDENT ACCOUNTANT. THE COMMITTEE CONTINUES TO MEET WITH THE INDEPENDENT AUDITOR AT THE CONCLUSION OF THE ANNUAL AUDIT. PART XI, LINE 8, PRIOR PERIOD ADJUSTMENT DURING 2016, MANAGEMENT WAS NOTIFIED THAT THE DONOR OF A $100,000 IRREVOCABLE SECOND-TO-DIE LIFE INSURANCE POLICY HAD CHANGED THE TERMS OF THE DONATION AND REMOVED THE FOUNDATION AS A BENEFICIARY. AN ADJUSTMENT OF $37,970 TO TEMPORARILY RESTRICTED NET ASSETS AS OF JANUARY 1, 2015 IS REFLECTED IN A DECREASE OF NET ASSETS FROM $3,311,450 TO $3,273,480. THE 2015 AUDITED FINANCIAL STATEMENTS HAVE BEEN REVISED TO REFLECT THE CHANGES IN THE TERMS. ADDITIONALLY, A $50,000 GRANT WAS RETURNED DURING 2016. THE CHANGE TO NET ASSETS AS A RESULT OF THESE PRIOR PERIOD ADJUSTMENTS IS A NET INCREASE OF $12,030.